Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
Clinical trial access in the United States faces a growing competitiveness crisis as other nations, including China, accelerate their biomedical innovation pipelines. The FAIR Act addresses this by establishing a harmonized, accelerated 30-day review pathway for clinical trials and therapies already approved by trusted...
Wet age-related macular degeneration (AMD) represents a leading cause of irreversible vision loss, characterized by the growth of abnormal blood vessels in the macula. While anti-VEGF therapies have revolutionized care by converting wet AMD back to a dry state, these treatments necessitate frequent, burdensome eye inje...
The FDA recently solidified its leadership by appointing permanent directors for CBER and CDER, aiming to restore institutional stability following recent regulatory controversies. Concurrently, the agency is prioritizing the regulation of psychedelic therapies and the reshoring of early-stage clinical trials through t...
Novartis and Bristol-Myers Squibb have paused several CAR T trials for autoimmune conditions following patient deaths and safety concerns, highlighting potential risks associated with rapid manufacturing processes. Meanwhile, the White House has expanded its Most Favored Nation drug pricing initiative to include nine m...
The biopharmaceutical sector faces significant shifts as companies navigate regulatory hurdles and pipeline transitions. Capricor Therapeutics received a three-month FDA review extension for its Duchenne muscular dystrophy cell therapy, deramiocel, amid intense scrutiny and shareholder demands for strategic changes. Me...
The biotech industry faces a mix of clinical breakthroughs and regulatory challenges, headlined by Amylyx’s positive Phase 3 data for its GLP-1 blocker, Avexitide, which demonstrated a 55% reduction in hypoglycemic events following bariatric surgery. Conversely, Summit Therapeutics faces mounting pressure regarding its...
Treatment-resistant depression (TRD) stems from the inherent biological heterogeneity of major depressive disorder, rendering traditional monoaminergic therapies ineffective for a significant patient subset. Current treatment paradigms rely on repetitive, daily medication, which often fails to address the underlying co...
Bristol Myers Squibb and AstraZeneca are reportedly in talks regarding a potential mega-merger that would create the largest pharmaceutical company in history, though analysts remain skeptical due to significant antitrust concerns and potential product overlap in oncology. Meanwhile, the pharmaceutical industry navigat...
Arvinas CEO Randy Teel details the strategic pivot from a late-stage commercial focus to an early-stage, platform-driven pipeline. Following the FDA approval and subsequent outlicensing of their lead asset, the company reallocated capital toward Phase 1 programs in oncology and neurology. Success during such inflection...
Follow this podcast in Podwise
Sign in to get AI summaries, transcripts and mind maps for any episode, including new ones.
